0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

4′-(9-Acridinylamino) Methanesulfon-m-Anisidide (AMSA): A New Drug Effective in the Treatment of Adult Acute Leukemia

SEWA S. LEGHA, M.D.; MICHAEL J. KEATING, M.D.; AXEL R. ZANDER, M.D.; KENNETH B. McCREDIE, M.D.; GERALD P. BODEY, M.D.; and EMIL J. FREIREICH, M.D.
[+] Article and Author Information

▸Requests for reprints should be addressed to Sewa S. Legha, M.D.; Department of Developmental Therapeutics, M. D. Anderson Hospital and Tumor Institute, 6723 Bertner; Houston, TX 77030.


Houston, Texas


© 1980 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1980;93(1_Part_1):17-21. doi:10.7326/0003-4819-93-1-17
Text Size: A A A

Sixty-two adults with previously treated acute leukemia were treated with 4′-(9-acridinylamino) methanesulfon-m-anisidide (AMSA) with a total dose of 150 mg to 1320 mg/m2 of body surface area given over 3 to 14 days intravenously. Of the 56 patients who received an adequate trial, 13 achieved a complete remission and six had a partial remission. The best therapeutic results were observed when AMSA was used at a dose level of 75 to 90 mg/m per day for 7 days, which resulted in nine complete remissions among 30 patients. Eleven of 38 patients with myeloblastic leukemia achieved complete remission, and three of 13 with lymphoblastic disease achieved partial remission. Complete remissions were observed in nine of 39 patients who were refractory to cytarabine and anthracyclines, indicating a lack of cross-resistance between these drugs and AMSA. The median duration of remission was 12 weeks, and the median survival of responders was 28.5 weeks. The major toxicity of AMSA therapy was severe myelosuppression resulting in frequent infections during induction therapy. Our results indicate that AMSA has significant activity against refractory adult acute leukemia and deserves further evaluation.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)